- Home
- TALKW vs BMRN Comparison
TALKW vs BMRN Comparison
Compare TALKW & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TALKW
- BMRN
- Stock Information
- Founded
- TALKW 2012
- BMRN 1996
- Country
- TALKW United States
- BMRN United States
- Employees
- TALKW 521
- BMRN N/A
- Industry
- TALKW Medical/Nursing Services
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- TALKW Health Care
- BMRN Health Care
- Exchange
- TALKW Nasdaq
- BMRN Nasdaq
- Market Cap
- TALKW N/A
- BMRN 12.1B
- IPO Year
- TALKW N/A
- BMRN 1999
- Fundamental
- Price
- TALKW $0.07
- BMRN $55.65
- Analyst Decision
- TALKW
- BMRN Buy
- Analyst Count
- TALKW 0
- BMRN 22
- Target Price
- TALKW N/A
- BMRN $93.43
- AVG Volume (30 Days)
- TALKW 64.2K
- BMRN 2.2M
- Earning Date
- TALKW 02-20-2025
- BMRN 08-04-2025
- Dividend Yield
- TALKW N/A
- BMRN N/A
- EPS Growth
- TALKW N/A
- BMRN 152.82
- EPS
- TALKW N/A
- BMRN 2.71
- Revenue
- TALKW $181,291,000.00
- BMRN $2,950,227,000.00
- Revenue This Year
- TALKW N/A
- BMRN $12.23
- Revenue Next Year
- TALKW N/A
- BMRN $9.99
- P/E Ratio
- TALKW N/A
- BMRN $20.77
- Revenue Growth
- TALKW 31.50
- BMRN 19.36
- 52 Week Low
- TALKW $0.20
- BMRN $52.93
- 52 Week High
- TALKW $0.24
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- TALKW N/A
- BMRN 40.03
- Support Level
- TALKW N/A
- BMRN $53.76
- Resistance Level
- TALKW N/A
- BMRN $55.96
- Average True Range (ATR)
- TALKW 0.00
- BMRN 1.17
- MACD
- TALKW 0.00
- BMRN 0.09
- Stochastic Oscillator
- TALKW 0.00
- BMRN 26.00
About TALKW Talkspace Inc. Warrant
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.